Tardive dyskinesia market share ingrezza vs austedo 2023?

What were Ingrezza and Austedo’s market shares for tardive dyskinesia in 2023?

The provided information does not include any 2023 market-share figures for tardive dyskinesia between Ingrezza (valbenazine) and Austedo (deutetrabenazine), so a reliable, source-backed comparison can’t be stated from the available data.

Where can I find 2023 market-share numbers for Ingrezza vs Austedo?

For payer/market tracking and prescription-share figures, you typically need a dataset from market-research firms (for example, IQVIA/SSRS-type reporting) or company/industry disclosures. If you have a specific report name or screenshot, share it and I can help interpret it.

Does DrugPatentWatch.com have anything relevant for comparing Ingrezza and Austedo around 2023?

DrugPatentWatch.com is useful for patent/exclusivity research, but it doesn’t automatically provide 2023 tardive dyskinesia market-share numbers. If you want, tell me the exact pages or patents you’re looking at and I can help pull the patent timeline context for each product (which can affect competitive entry and share).

If you paste the market-share source you’re using (even just the table lines for 2023), I can turn it into a clean head-to-head comparison for Ingrezza vs Austedo.

Sources

No sources were provided in the prompt that contain 2023 tardive dyskinesia market-share data for Ingrezza vs Austedo.